ClinicalTrials.gg
CompletedNCT05176158Updated Dec 4, 2024

Dexketoprofen Dosage According to Chronotherapy

An interventional study of Dexketoprofen 25 MG and Dexketoprofen 25 MG in Tooth, Impacted, Trismus and Pain, sponsored by Universidad Complutense de Madrid. Completed at 1 site in Spain. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by Universidad Complutense de Madrid · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

Lower third molar extraction is one of the most common treatments in oral surgery practice. It is a treatment with inherent complications such as postoperative pain, swelling or trismus. In order to minimize disconfort after extraction, analgesic and anti-inflammatory medication is prescribed. Recently, it is seen that circadian rhythm may play an important role on drugs metabolism, modulating its effect depending on the moment of administration.

The aim of the study is to analyze if dosage modification of a Non Steroideal Anti-Inflammatory (dexketoprofen) affects on postoperative pain, swelling and open mouth limitation according the circadian clock

Read the detailed description

A randomized crossover split-mouth clinical trial will be performed. After third molar extractions, patients will be prescribed randomly in one side intake morning medication dosage while the contralateral side will be prescribed a night dosage. Moreover, a blood sample will be obtained to analyze the inflammatory profile.

02

Conditions studied

  • Tooth, Impacted
  • Trismus
  • Pain
  • Inflammatory Response

Keywords

  • Third
  • Dexketroprofen
  • Randomized
03

In context

Tooth, Impacted

122 studies on the registry are indexed under Tooth, Impacted; 15 are open to participants now.

This study's enrollment of 10 is below the median of 70 across 88 interventional studies indexed under Tooth, Impacted.

Browse Tooth, Impacted studies →

Lead sponsor

Universidad Complutense de Madrid is the lead sponsor of 206 studies on the registry; 64 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Bilateral impacted lower third molar

Exclusion criteria

Exclusion Criteria:

  • NSAID allergic
  • of surgery
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Morning dosage

    Dexketoprofen pill at morning; Placebo at night

    Drug: Dexketoprofen 25 MG

  • Experimental
    Night dosage

    Placebo pill at morning; Dexketoprofen at night

    Drug: Dexketoprofen 25 MG

Interventions

06

What researchers measure

Primary outcomes

  1. Post operatory pain

    Postoperatory pain with Visual Analogue Scale (VAS: 0 (no pain) to 10 (worst pain))

    Time frame: From the day of the surgical procedure to the seventh-day

Secondary outcomes

  1. Swelling

    Distance from tragus to pogonion

    Time frame: Baseline and post operatory (day 1, day 3, day 7)

Other outcomes

  1. Trismus

    Open mouth limitation in milimiters, interincisal distance

    Time frame: Baseline and post operatory (day 1, day 3 and day 7)

  2. Inflammatory profile for IL-1B, IL-6, IL-8, IL-10, TNF alpha

    Blood sample analysis for inflammatory cytokines in IU/ml by ELISA test (enzyme-linked immunoassay)

    Time frame: Baseline, day 3 and day 7

07

Study locations

1 site
  • UCM
    Madrid, 28040, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05176158
Collaborators
McGill University
Responsible party
Jesús Torres García Denche (Associate professor, Universidad Complutense de Madrid) — Principal investigator
First posted
Jan 4, 2022
Start date
Nov 1, 2024
Primary completion
Nov 1, 2024
Completion
Nov 1, 2024
Last update
Dec 4, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexketoprofen

Start the discussion